Erwin van Wijk (born in 1975) is an Associate Professor at the Department of Otorhinolaryngology of Radboudumc, Nijmegen, The Netherlands. He heads a research team dedicated to develop new antisense oligonucleotide-based splice modulation therapies for Usher Syndrome, using zebrafish as an animal. His team obtained pre-clinical therapeutic proof of concept for multiple USH2A targets using this approach. One of the molecules has already been evaluated in a phase I/II clinical trial, with promising outcomes. At the moment, his team is also working on the phenotypic analysis and development of innovative treatments for other types of Usher syndrome.
Chief Executive Officer
Chief Operational Officer, Founder, Key opinion leader Retinal Disease
Chief Scientific Officer, Founder, Inventor RNA Therapy
Irene Vázquez Domínguez